Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Schering-Plough, Sepracor Sign Deal to End Clarinex Exclusivity in 2012
- Schering Plough and Sepracor have settled a patent dispute with Indian generics maker Dr. Reddy's over Clarinex. The settlement brings forward the end of patent exclusivity on Clarinex to 2012. Previously, the assumption had been that Schering's exclusivity with Clarinex would last until 2020. The terms of...
- Blog posts 2008-12-29
Additional Resources
- HMO wants Clarinex switched to OTC
- A California-based HMO that fought for years to get the FDA to force an over-thecounter OTC switch of three popular allergy drugs is now asking the agency to force an OTC switch on Schering-Ploughs Claritin successor, Clarinex. Wellpoint Health Networks petitioned the FDA in April for Clarinex's OTC switch, a...
- Research articles 2002-06-01
- SCHERING-Plough Corp.(negotiates launch of Clarinex with Food & Drug Administration)(Brief Article)
- SCHERING-Plough Corp. is said to be negotiating final terms of a consent decree with the Food & Drug Administration over manufacturing woes, which prevent a Clarinex launch. ... SCHERING-Plough Corp. is said to be negotiating final terms of a consent decree with the Food...
- Research articles 2001-10-22
- Drugmaker readies son of Claritin; New Schering-Plough allergy drug will likely bear the Clarinex name.(Brief Article)
- Schering-Plough's Corp.'s so-called son of Claritin will resemble its predecessor quite a bit. Schering-Plough hopes to dub the blockbuster allergy drug's successor Clarinex, according to people familiar with the matter. Schering-Plough is awaiting a Schering-Plough's Corp.'s so-called son of Claritin will resemble its predecessor quite...
- Research articles 2000-08-07
- Clarinex approval sets FDA precedent
- Mo. The FDA's approval of Schering's Clarinex desloratadine on December 21 for "the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older" broke an internal policy precedent by being based not on an FDA preapproval inspection of the plant that...
- Research articles 2002-02-01
- How to follow a blockbuster? ; Schering studies Clarinex options.(Schering-Plough meets with Robert A. Becker Euro RSCG)(Brief Article)
- Executives at Schering-Plough started wheezing earlier this year when Uncle Sam turned anything but avuncular and delayed marketing clearance for the successor to blockbuster allergy drug Claritin. The move, postponing the glitzy launch of Clarinex, Executives at Schering-Plough started wheezing earlier this year when...
- Research articles 2001-11-19
- Schering-plough vies to quash generic OTC claritin. (Life Sciences).(Has filed separate suits against divisions of Johnson & Johnson and American Home Products Corp.)(Brief Article)
- IN A MOVE to block generic over-the-counter OTC competition for its $3.2 billion antihistamine Claritin loratadine and lock-in sales of Clarinex desloratadine, a newly launched successor, Schering-Plough Corp. SHP has filed separate suits a IN A MOVE to block generic over-the-counter OTC competition for...
- Research articles 2002-02-11
- Manufacturing Problems Cast Pall on Schering-Plough Earnings.(Statistical Data Included)
- Food & Drug Administration has made the approval of Clarinex contingent on compliance. Food & Drug Administration has made the approval of Clarinex contingent on compliance.
- Research articles 2001-07-09
- Schering-Plough becomes vulnerable to takeover. (Life Sciences).(Brief Article)
- THE POSSIBILITY of a takeover of Schering-Plough Corp. SHP intensified last week as the company faced declining valuation amidst uncertainty over its $3.2 billion antihistamine Claritin loratadine/Clarinex desloratadine franchise. THE POSSIBILITY of a takeover of Schering-Plough Corp. SHP intensified last week...
- Research articles 2002-02-18
- Schering-Plough Faces Uncertain Future In Wake of Manufacturing Problems.(Brief Article)(Statistical Data Included)
- IN THE WAKE OF manufacturing problems for Clarinex desloratadine, Schering-Plough Corporation's successor to its top-selling non-sedating antihistamine Claritin loratadine, the company and analysts have lowered their financial expectations. IN THE WAKE OF manufacturing problems for Clarinex desloratadine, Schering-Plough Corporation's successor to...
- Research articles 2001-02-26
- CommonHealth's Quantum Group Named DTC Agency Of The Year; Agency's Campaign Aids in Schering-Plough's Clarinex Win for "Brand of the Year"
- Business Editors
- Research articles 2002-11-14
- CLARINEX Information and Pollen Forecast Now Available to Patients Using AvantGo Software on PDAs
- Business Editors & High-Tech/Health/Medical Writers
- Research articles 2003-01-13
- Schering Laboratories to Use AOL Time Warner Cross-Platform Marketing Campaign as Part of New CLARINEX Direct-to-Consumer Educational Program
- Business/Technology Editors
- Research articles 2002-03-04
- Schering-Plough Wages Ad Campaign to Shift Patients to Clarinex.
- By Bernard J. Wolfson, The Orange County Register, Calif. Knight Ridder/Tribune Business News By Bernard J. Wolfson, The Orange County Register, Calif. Knight Ridder/Tribune Business News
- Research articles 2002-08-07
- Drug Royalty To Benefit From Schering-Plough's FDA Approval Of CLARINEX(R) (Desloratadine) For Treatment Of Seasonal Allergic Rhinitis.
- TORONTO, ONTARIO, JANUARY 2, 2002 TORONTO, ONTARIO, JANUARY 2, 2002
- Research articles 2002-01-02
- Clarinex ready to go ; Schering preps marketing effort while waiting for FDA green light.
- Schering-Plough will use a futuristic logo to introduce its eagerly anticipated successor to the blockbuster drug Claritin, now in the final stages of government approval. Schering-Plough will use a futuristic logo to introduce its eagerly anticipated successor to the blockbuster drug Claritin, now in...
- Research articles 2001-01-29
- Insurance Industry Experiences Huge Increase in Mold Claims by Homeowners.
- The Miami Herald Knight Ridder/Tribune Business News Jul. 29--Amado Valdes, 61, keeps a jar of Cetaphil skin cream by his bed, to soothe the itchy dark welts on his hands and neck. A humidifier bubbles at night to moisten his lungs and calm...
- Research articles 2002-07-29
- J&J vs. Merck and Schering: Who Is Most Desperate in This Bizarre Love Triangle?
- Nobody wants to say anything about the great Remicade tug of war that has broken out between Johnson & Johnson and the soon-to-be-merged Merck and Schering-Plough. A look at the Q1 2009 numbers suggest that each member of this trio has their own reasons to be quietly...
- Blog posts 2009-04-24
- New name brings game
- Agency of the Year Saatchi + Saatchi Healthcare There were many worthies in the agency world in 2005, but Saatchi & Saatchi Healthcare Communications topped everyone for eye-popping account wins-like Crestor, Clarinex and Avelox-and stellar, highly visible creative. The Publicis Groupe unit, formed from a merger of Saatchi...
- Research articles 2006-01-01
- << Previous
- page 1 of 1
- Next >>
